BioCreate Program


Ontario Genomics



BioCreate program banner showing the Canada and Ontario Genomics logo

Ontario Genomics’ BioCreate program is open to small- and medium-sized enterprises (SMEs) in southern Ontario seeking to commercialize genomics and engineering biology enabled products and/or technologies in the health, food and agriculture, and cleantech sectors who have achieved a Technology Readiness Level (TRL) of 4+. BioCreate will provide funding, access to mentorship and business support to enable companies to raise additional financing to achieve commercial outcomes.

The multi-phase BioCreate program will include direct, non-repayable funding of $150,000 that will be matched by an additional $100,000 (minimum – cash and/or in-kind) from participating companies to a total project size of $250,000 or more. Funded companies will have access to 18-months of intensive business mentorship and access to critical infrastructure provided by Ontario Genomics’ (OG’s) strategic sectoral and regional partnerships. Each cohort will conclude with an investor showcase, giving the companies an opportunity to pitch to investors and potential partners. BioCreate will support up to 32 high-potential companies over five years with seven total cohorts (rolling intake with funding decisions twice per year).

The BioCreate program consists of three phases:

The BioCreate expert panel will evaluate market potential and technical feasibility of eligible applications, based on the evaluation criteria defined in the Program Guide. Successful applicants will receive up to $150,000 in non-repayable funding and must contribute $100,000 minimum (cash and/or in-kind) to leverage the funding for their 18-month project. The application process consists of three stages:

  • Expression of interest
  • Invitation to submit application/submission of written application
  • Pitch to BioCreate Expert Panel

During the course of the funded project, the BioCreate program will support technology and business development to successful applicants through business mentors, patent expertise, regulatory support, and other support as defined by the needs of the company. Access to infrastructure can be facilitated through our program partners depending on company needs and location. OG’s strategic sectoral and regional partnerships include Velocity (Waterloo), Synapse Life Sciences Consortium (Hamilton), Toronto Metropolitan University SDZ (Toronto),  Cleantech Commons (Peterborough) and UofT SpinUp (Mississauga). SMEs will also work with one or more BioCreate partners and Ontario Genomics BioCreate team to develop a pitch deck to present at the Investor Showcase in Phase III.

After the successful completion of the 18-month program, teams will participate in an investor showcase where they will pitch to an audience of regional enablers and investors in efforts to receive follow-on investment.


Biocreate header with three phases

Application Steps and Dates

Interested SMEs should register and submit a BioCreate intake form. A representative from the BioCreate team will reach out to you to discuss your project idea. Competitive applicants will be invited to submit an application.

For more information on the BioCreate program including eligibility requirements and evaluation criteria see the Program Guide. If you have questions, please contact BioCreate.

As a signatory to the 50-30 Challenge, Inclusivity, Diversity, Equity and Accessibility (IDEA) is a core component of Ontario Genomics’ ethos, including within this program. Furthermore, Ontario’s population is highly diverse, and effective and authentic diversity and inclusion strategies are essential for southern Ontario organizations to thrive and achieve their goals. We encourage applications from diverse teams and all equity-deserving groups.

BioCreate is a 5-year, 11.6 million dollar program supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) and by Ontario Genomics.



Key Dates

A total of 8 companies will be funded this year on a rolling intake throughout the year – in the timelines below

Phase I – BioCreate Funding

  • Register and submit the BioCreate intake form in our new portal.
  • Intake start date: April 10, 2024
  • Deadline to submit intake form to be considered for Cohort 4/5 is June 23, 2024
  • Intake call with OG’s BioCreate team
  • Full applications are due July 28, 2024
  • Company pitch to BioCreate expert panel – November 2024
  • Notification of award – December 2024
  • Contract executed – end of December 2024

Phase II – BioCreate Business Mentorship

  • Initiated in January 2025

Cohort closed – Projects launched April 1, 2024.

Learn more about the 4 awarded companies of the BioCreate Cohort 3

Important: updates to Cohort 3 eligibility (in addition to the eligibility criteria in the program guide). For this cohort, eligible companies will be pre-revenue and have raised between $0-2M in funding (including grants). For early-stage companies, some revenue generated through non-core business activities may be permissible, as assessed on a case-by-case basis.

Reason for the update: The BioCreate program seeks to treat all eligible applicants fairly and equitably during the application and review process, where the $150K grant facilitates a meaningful impact leading to company growth and success in Ontario. The definition of “SME” as stated in our program guide is broad and includes a wide range of company sizes. The cap on revenue and funding for cohort 3 allows for a fair competition for earlier-stage companies within the broad definition of “SMEs”. Our goal is to support SMEs who have achieved TRL 4+ and are commercializing innovative Ontario-based genomics and engineering biology solutions. This update applies only to cohort 3, and we will continue to reassess our program going forward in a way that strives to provide a fair, diverse, and balanced opportunity for SMEs in this space.

Cohort closed – Projects launched October 1, 2023.

Learn more about the 4 awarded companies of the BioCreate Cohort 2

Cohort closed – Projects launched April 1, 2023.

Learn more about the 8 awarded companies of the BioCreate Cohort 1

Awarded projects